Pharmacology: January 2008 Archives

A case report published in the Journal of Neuroinflammation gives hope to patients with Alzheimer's disease and their carers. Rapid cognitive improvement was seen within minutes in a patient with late-onset Alzheimer's disease following perispinal etanercept (an anti-TNF drug). Previous research has suggested that excess tumour necrosis factor-alpha (TNF-alpha) is centrally involved in the pathogenesis of Alzheimer's disease. It has recently been shown to mediate the disruption in synaptic memory mechanisms, which is caused by beta-amyloid and beta-amyloid oligomers. The beneficial effects seen with etanercept may be related to amelioration of the effects of excess TNF-alpha on synpatic mechanisms in Alzheimer's disease.